Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Flupirtine
Clinical features of neuromyelitis optica in children: US Network of Pediatric MS Centers report.
Clinical utility of the list sign as a predictor of non-demyelinating disorders in a multiple sclerosis (MS) practice.
Visualizing Non-Gaussian Diffusion: Clinical Application of q-Space Imaging and Diffusional Kurtosis Imaging of the Brain and Spine.
American Society for Neurochemistry Annual Meeting
Estriol Treatment in Multiple Sclerosis: Effect on Cognition
IFNbeta lowers MMP-9/TIMP-1 ratio, which predicts new enhancing lesions in patients with SPMS.
Clinical utility of testing AQP4-IgG in CSF: Guidance for physicians.
A gender gap in autoimmunity.
Clinical and radiologic rebound after discontinuation of natalizumab therapy in a highly active multiple sclerosis patient was not halted by dimethyl-fumarate: a case report.
Attenuation of 7-ketocholesterol-induced overproduction of reactive oxygen species, apoptosis, and autophagy by dimethyl fumarate on 158N murine oligodendrocytes.
Glatiramer acetate has no impact on disease progression in ALS at 40 mg/day: a double- blind, randomized, multicentre, placebo-controlled trial.
Systemic recombinant human interferon-beta treatment of relapsing-remitting multiple sclerosis: pilot study analysis and six-year follow-up.
Teriflunomide for multiple sclerosis.
Statement on a nonproprietary name adopted by the USAN Council
Genzyme reports positive top-line results of TOWER, a pivotal phase III trial for AUBAGIO(TM*) (teriflunomide) in relapsing multiple sclerosis
Pharmacokinetics, pharmacodynamics, and safety of peginterferon beta-1a in subjects with normal or impaired renal function.
Weekly vaccination with Copaxone (glatiramer acetate) as a potential therapy for dry age-related macular degeneration.
Evaluation of circulating osteopontin levels in an unselected cohort of patients with multiple sclerosis: relevance for biomarker development.
PLEGRIDY® (Peginterferon Beta-1a) Three-Year Data Presented at AAN Annual Meeting Support Long-Term Safety and Efficacy in Multiple Sclerosis Patients
Information for healthcare professionals: Rituximab
Microcystic macular oedema in multiple sclerosis is associated with disease severity.
Ruxolitinib synergizes with DMF to kill via BIM+BAD-induced mitochondrial dysfunction and via reduced SOD2/TRX expression and ROS.
Merck: Regulatory Update on Cladribine Tablets
Adaptive autoimmunity and Foxp3-based immunoregulation in zebrafish.

Pages